65 related articles for article (PubMed ID: 21442199)
21. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
22. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
Campone M; Cortes-Funes H; Vorobiof D; Martin M; Slabber CF; Ciruelos E; Bourbouloux E; Mendiola C; Delgado FM; Colin C; Aslanis V; Fumoleau P
Br J Cancer; 2006 Nov; 95(9):1161-6. PubMed ID: 17031408
[TBL] [Abstract][Full Text] [Related]
23. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
24. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.
Isambert N; Delord JP; Tourani JM; Fumoleau P; Ravaud A; Pinel MC; Petain A; Nguyen T; Nguyen L
Br J Clin Pharmacol; 2014 Mar; 77(3):498-508. PubMed ID: 24283925
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.
Bennouna J; Fumoleau P; Armand JP; Raymond E; Campone M; Delgado FM; Puozzo C; Marty M
Ann Oncol; 2003 Apr; 14(4):630-7. PubMed ID: 12649112
[TBL] [Abstract][Full Text] [Related]
26. Vinflunine for the treatment of breast cancer.
Gourmelon C; Bourien H; Augereau P; Patsouris A; Frenel JS; Campone M
Expert Opin Pharmacother; 2016 Sep; 17(13):1817-23. PubMed ID: 27484180
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
Bates SE; Meadows B; Goldspiel BR; Denicoff A; Le TB; Tucker E; Steinberg SM; Elwood LJ
Cancer Chemother Pharmacol; 1995; 35(6):457-63. PubMed ID: 7882454
[TBL] [Abstract][Full Text] [Related]
28. Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.
Bamias A; Hegele A; Medioni J; Castellano D; Doni L; Passalacqua R; Zagouri F; Tzannis K; Hussain S; Ullen A
Crit Rev Oncol Hematol; 2019 Aug; 140():80-87. PubMed ID: 31133463
[TBL] [Abstract][Full Text] [Related]
29. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
[TBL] [Abstract][Full Text] [Related]
30. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Catania C; Maur M; Berardi R; Rocca A; Giacomo AM; Spitaleri G; Masini C; Pierantoni C; González-Iglesias R; Zigon G; Tasciotti A; Giovannoni L; Lovato V; Elia G; Menssen HD; Neri D; Cascinu S; Conte PF; Braud Fd
Cell Adh Migr; 2015; 9(1-2):14-21. PubMed ID: 25562532
[TBL] [Abstract][Full Text] [Related]
31. Vindesine in the treatment of metastatic breast cancer.
Hansen PV; Brincker H
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1221-5. PubMed ID: 6541581
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
Matsumura Y; Hamaguchi T; Ura T; Muro K; Yamada Y; Shimada Y; Shirao K; Okusaka T; Ueno H; Ikeda M; Watanabe N
Br J Cancer; 2004 Nov; 91(10):1775-81. PubMed ID: 15477860
[TBL] [Abstract][Full Text] [Related]
33. Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.
Schmitt A; Nguyen L; Zorza G; Ferré P; Pétain A
Br J Clin Pharmacol; 2018 May; 84(5):900-910. PubMed ID: 29341179
[TBL] [Abstract][Full Text] [Related]
34. 4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.
Samonigg H; Kasparek AK; Stöger H; Schmid M; Eber B; Stark G; Weinrauch V; Pfeiffer K; Smola M; Steindorfer P
Cancer Chemother Pharmacol; 1990; 26(4):293-6. PubMed ID: 2369794
[TBL] [Abstract][Full Text] [Related]
35. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.
Bonfil RD; Russo DM; Binda MM; Delgado FM; Vincenti M
Urol Oncol; 2002; 7(4):159-66. PubMed ID: 12474532
[TBL] [Abstract][Full Text] [Related]
36. [Intrabiliary administration of doxorubicin for pancreaticobiliary cancer].
Nagahama T; Maruyama M; Nakamura N; Irie T; Yoshida T; Kure N; Ebuchi M
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1849-52. PubMed ID: 10560410
[TBL] [Abstract][Full Text] [Related]
37. Vinflunine in the treatment of bladder cancer.
Bachner M; De Santis M
Ther Clin Risk Manag; 2008 Dec; 4(6):1243-53. PubMed ID: 19337431
[TBL] [Abstract][Full Text] [Related]
38. Vinflunine: clinical perspectives of an emerging anticancer agent.
Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Delord JP; Ravaud A; Bennouna J; Fumoleau P; Favrel S; Pinel MC; Ferré P; Saliba F
Invest New Drugs; 2013 Jun; 31(3):724-33. PubMed ID: 22996801
[TBL] [Abstract][Full Text] [Related]
40. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
Bonfante V; Bonadonna G; Villani F; Martini A
Recent Results Cancer Res; 1980; 74():192-9. PubMed ID: 6934564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
